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ABSTRACT
The ETS domain transcription factor Elk-1 stimu-
lates expression of immediate early genes (IEGs) in
response to mitogens. These events require phos-
phorylation of Elk-1 by extracellular signal-regulated
kinase (ERK) and phosphorylation-dependent inter-
action of Elk-1 with co-activators, including histone
acetyltransferases and the Mediator complex. Elk-1
also recruits ERK to the promoters of its target
genes, suggesting that ERK phosphorylates add-
itional substrates in transcription complexes at
mitogen-responsive promoters. Here we report that
MED14, a core subunit of the Mediator, is a bona
fide ERK substrate and identify serine 986 (S986)
within a serine-proline rich region of MED14 as the
major ERK phosphorylation site. Mitogens induced
phosphorylation of MED14 on S986 at IEG pro-
moters; RNAi knockdown of MED14 reduced CDK8
and RNA polymerase II (RNAPII) recruitment, RNAPII
C-terminal domain phosphorylation and impaired
activation of IEG transcription. A single alanine
substitution at S986 reduced activation of an E26
(ETS)-responsive reporter by oncogenic Ras and
mitogen-induced, Elk-1-dependent transcription,
whereas activities of other transcriptional activators
were unaffected. We also demonstrate that Elk-1
can associate with MED14 independently of
MED23, which may facilitate phosphorylation of
MED14 by ERK to impart a positive and selective
impact on mitogen-responsive gene expression.
INTRODUCTION
The speciﬁc and temporal co-ordination of gene expres-
sion is a fundamental process of cell-based life with
patterns of gene expression controlling proliferation, dif-
ferentiation and cell death. Immediate early gene (IEG)
expression has revealed how crucial regulatory events
revolve around the interface between pathway-speciﬁc
transcription factors and components of the transcription
machinery, involving a plethora of protein interactions
and modiﬁcations (1,2).
The ternary complex factor (TCF) Elk-1, an E26 (ETS)
transcription factor family member, activates transcription
of multiple IEGs in response to mitogens, a process
initiated upon Elk-1 phosphorylation by the mitogen-
activated protein kinases (MAPKs) extracellular signal-
regulated kinase (ERK)1 and ERK2 (ERK) (3–5).
Phosphorylation increases the afﬁnity of Elk-1 for Serum
Response Element (SRE)-containing promoters, which it
engages in a complex with Serum Response Factor (SRF)
(6), and correlates with desumoylation and derepression of
Elk-1 to unleash its trans-activation potential (7,8). One
means by which Elk-1 stimulates IEG expression is
through the recruitment of histone acetyltransferases and
concomitant alterations in nucleosome positioning, pre-
sumably facilitating promoter access and the establishment
of pre-initiation complexes (PICs) (9).
RNA polymerase II (RNAPII) recognizes and engages
promoters with the assistance of several basal transcrip-
tion factors and accompanied by a multi-protein complex
referred to as Mediator (10). Biochemical and structural
analyses have revealed the mammalian Mediator to
consist of up to 30 subunits with a mass of 1.5 MD in
a head-body-tail arrangement plus auxiliary Cyclin-
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Dependent Kinase 8 (CDK8) module (11,12). In conjunc-
tion with regulatory transcription factors, Mediator
appears to co-ordinate phospho-isomerization of the
carboxy-terminal domain (CTD) of RNAPII that
accompanies promoter escape and the switch to elong-
ation (13). The role of the CDK8 module in these events
is somewhat controversial, as evidence supports a repres-
sor function at the level of initiation (14) but a stimulatory
role during elongation (15). Thus the relationship between
regulatory transcription factors, Mediator and the CDK8
module has become a major focus of studies on transcrip-
tional regulation (16).
Elk-1 appears to communicate with Mediator via inter-
actions with the MED23 subunit (aka Sur2, CRSP130,
DRIP130) (17). This interaction appears dependent on
phosphorylation of Elk-1 and is essential for Elk-1-
dependent gene regulation in several contexts, including
insulin-dependent adipocyte differentiation (18). What
remains unclear is the nature of the interaction and its
effect on the function of MED23 or indeed Mediator
itself. We have shown that ERK is recruited to the pro-
moters of IEGs by Elk-1 and inferred that ERK may
phosphorylate additional substrates in PICs assembled
on IEG promoters (19). Here we reveal the Mediator
subunit MED14 as a novel ERK substrate, detect Elk-1
interactions with MED14 that are independent of
MED23, demonstrate inducible phosphorylation of
MED14 at IEG promoters and provide evidence for its
positive role in mitogen-responsive gene transcription.
MATERIALS AND METHODS
Cell culture, transfections and extract preparation
HEK293, HEK293T, HeLa and NIH3T3 cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum
(FCS), 2mM L-glutamine, 100U ml1 penicillin and
100mgml-1 streptomycin. HCT116 cells were cultured
in McCoy’s 5A medium supplemented with 10% FCS
(Hyclone) and antibiotic/antimycotic mix (Gibco). Wild
type and MED23/ Murine Embryonic Fibroblasts
(MEFs) were cultured in DMEM (Sigma D5671) supple-
mented with 15% FCS, 4mM L-glutamine, 100U ml1
penicillin and 100mgml-1 streptomycin. Cells were trans-
fected according to standard procedures. Whole-cell
lysates were prepared in RIPA buffer; nuclear and cytoplas-
mic extracts were prepared as described elsewhere (20).
Elk-1 knockdown was performed as described previ-
ously (19). For MED14 knockdown in HeLa cells a com-
bination of two Silencer Select siRNAs (Ambion) were
transfected with siPORT reagent according to the manu-
facturer’s instructions. Lentiviral knockdown in HCT116
cells was performed as described previously (15).
Antibodies, immunopreciptations and immunoblotting
The antibodies used in this study are listed in
Supplementary Table S1. The rabbit anti-phospho-S986
polyclonal antibody was raised against a phospho-
peptide coupled to keyhole limpet haemocyanin and
afﬁnity puriﬁed with peptides coupled to sepharose
beads. Co-immunoprecipitations and immunoblotting
were carried out as detailed in Supplementary
Information.
Plasmids
The expression vectors used in this study are listed in
Supplementary Table S2. Vectors for MED14 and
GST-MED14-SPR were generated by standard procedures;
point mutagenesis was by a polymerase chain reaction
(PCR)-based protocol (QuickChange, Stratagene).
In vitro kinase assays
Immobilized PICs, prepared as described earlier (19), were
incubated in transcription buffer containing 32P-g-ATP.
Glutathione-S-transferase (GST) fusion proteins (1 mg)
on sepharose beads or FLAG-/HA-tagged Mediator
subunits immunoprecipitated from lysates of HEK293/
293T cells were incubated with active recombinant
ERK2 (rERK2*) (0.25 mg) and 32P-g-ATP as described
earlier (19). ERK inhibitors I and II (Calbiochem) were
used at 30 and 8.5 mM; Roscovitine was used at 30 mM.
Quantitative reverse transcriptase PCR
The primers used in this study are listed in Supplementary
Table S3. Assays were performed as described in the sup-
plementary information.
Reporter assays
Cells in 24-well plates were lysed 36 h after transfection in
passive lysis buffer; Fireﬂy and Renilla levels were
analyzed with the Stop and Glow system (Invitrogen).
Chromatin immunoprecipitation assays
The primers used in this study, methods and data analysis
have all been described previously (15).
RESULTS
Identiﬁcation of potential ERK targets in mediator
Our earlier report on the recruitment of kinases to IEG
promoters described the presence of ERK in immobilized
PICs assembled in vitro on SRE promoters (19). In subse-
quent kinase assays, we reproducibly detected phosphor-
ylation of multiple proteins in PICs assembled on SRE
promoters in nuclear extracts from mitogen stimulated
cells (Figure 1a, lane 4) but not on basal promoters
or in nuclear extracts from mitogen starved cells (lanes
1–3). Unfortunately, we were unable to ascribe any of
these phosphorylation events unambiguously to ERK (un-
published data). However, an alternative candidate
approach did allow us to identify ERK substrates at
IEG promoters.
Several Mediator components had been identiﬁed in
SRE PICs and some appeared to be good candidate
ERK substrates, based on the presence of consensus
ERK phosphorylation sites and docking motifs (see
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Table 1). To test these proteins as ERK substrates we
immunoprecipitated tagged versions from cells for use in
kinase assays with rERK2*. Of the seven proteins ex-
pressed successfully in HEK293 cells, only MED14 was
phosphorylated in an ERK-dependent manner (Figure
1b, lower panels, lane 4). In further experiments, we con-
ﬁrmed this result and, in addition, demonstrated phos-
phorylation of MED1 and, weakly, MED15
(Supplementary Figure S1a lanes 6, 2 and 8). The lack
of a suitable expression vector precluded MED13 from
these analyses.
MED1 is a known ERK target (22) implicated together
with MED14 in differential gene regulation by the gluco-
corticoid receptor (23). The ERK substrate apparent in
MED12 immunoprecipitates (Supplementary Figure S1a,
lane 4, open arrowhead) is substantially smaller than
MED12 (240 kD) and could be a co-immunoprecipitated
protein or a fragment of MED12. MED14 has a similar
migration (see lane 6) and has been shown to co-purify
with the CDK8 complex, of which MED12 is a subunit
(14). However, although both MED12 and MED14
co-immunoprecipitate with CDK8 (Supplementary
Figure S1b), we did not detect MED14 in MED12
immunoprecipitates, and the identity of this protein
species remains open. We therefore focussed on the unre-
ported relationship between ERK and MED14.
Phosphorylation of MED14 by ERK in vitro
The carboxy-terminal half of MED14 includes an 200
residue region (aas 949–1147), with no obvious structural
clues but a series of serine-proline (SP) motifs including
several ERK consensus phosphorylation sites, that is
conserved among vertebrates and ﬂies (Figure 2a and b).
Proteomic studies have identiﬁed several MED14
phospho-peptides derived from this region (24–26). To
map potential ERK phosphorylation sites in MED14,
this SP-rich region (SPR domain) was ﬁrst expressed as
a recombinant GST fusion and tested as an ERK sub-
strate, then mutated to remove individual or multiple
sites. ERK phosphorylated the SPR domain efﬁciently
(Supplementary Figure S2a and Figure 2c, lanes 1 and
7). A single alanine substitution at S986 reduced phos-
phate incorporation by 90% (Figure 2c, compare lanes 1
and 2, 7 and 8), whereas mutations S1023A, S1128A,
S1095A and S1112A (lanes 3, 5, 9 and 11) had little
effect. Moreover, in combination with S986A only
S1095A caused any further decrease in phosphorylation
(compare lanes 8 and 10), suggesting that S986 is the pre-
dominant site for ERK phosphorylation within this region
of MED14.
In kinase assays with MED14 proteins immunopre-
cipitated from HEK293T cells, full-length MED14
was phosphorylated efﬁciently by ERK but MED14
lacking the SPR (MED14) was not (Supplementary
Figure S2b), conﬁrming that ERK phosphorylation was
conﬁned to the SPR domain. Single point mutations were
introduced into full-length MED14 at the same ﬁve sites
and, as seen with the recombinant SPR domain, S986A
had the most signiﬁcant effect, reducing ERK phosphor-
ylation of MED14 by 60% (Figure 2d, lane 2 and e).
Substitutions at other sites in combination with S986A
did not further reduce MED14 phosphorylation (data
Figure 1. Phosphorylation of PIC components and Mediator subunits
in vitro (a) Nuclear extracts from unstimulated (lanes 1 and 3) or
serum-stimulated (lanes 2 and 4) HeLa cells were used for PIC
assembly on TATA (lanes 1 and 2) or SRE (lanes 3 and 4) templates
as described earlier (19). Complexes were washed, incubated in tran-
scription buffer containing 32P-g-ATP and resolved by SDS-PAGE.
Gels were dried and visualized by phosphor-imaging (Fujiﬁlm).
Arrowheads indicate discrete radiolabeled species observed in multiple
independent experiments. (b) Epitope-tagged Mediator subunits were
expressed in HEK293 cells, immunoprecipitated from cell lysates with
FLAG or HA antibodies (arrowheads, upper panels) and subjected
to in vitro kinase assays with 32P-g-ATP in the absence () or
presence (+) of rERK2*. Reactions were separated by SDS-PAGE
and visualized by phosphor-imaging (lower panels). Bands correspond-
ing to auto-phosphorylated rERK2* are indicated by asterisks.
Table 1. Human mediator subunits with consensus ERK motifs





1 MED13 250 38 13 2 Yesb cdk
2 MED1 220 41 7 0 Yesc body
3 MED14 150 24 7 0 Yes tail
4 MED15 105 16 6 0 ND tail
5 MED26 70 17 5 0 Not ERK unassigned
6 MED12 240 15 3 0 Yes cdk
7 MED16 95 10 2 0 ND tail
8 MED9 25 4 2 0 ND body
9 MED25 82 5 1 0 ND unassigned
10 MED17 78 3 1 0 ND head
abased on (21), bMDG and PES, unpublished, c(22) and this work.
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Figure 2. Mapping ERK phosphorylation sites in MED14. (a) Diagram showing location of SPR domain in MED14, the MED14 deletion mutant
and the SPR domain of MED14 expressed as a recombinant protein. Black bars indicate ERK consensus sites screened by mutagenesis; gray bars
indicate other non-consensus S/TP motifs. (b) Alignment of hMED14 SPR domain with MED14 amino acid sequences from HomoloGene group
22082 using the MUSCLE algorithm. MAPK consensus sites are highlighted in black with phosphorylated SP motifs identiﬁed by phospho-prote-
omics marked with asterisks. NCBI accession numbers for the MED14 proteins compared are: NP_004220.2, Homo sapiens; XP_538001.2, Canis
familiaris; NP_001041673.1 Mus musculus; XP_228713.3, Rattus norvegicus; XP_416776.2, Gallus gallus; NP_612041.2, Drosophila melanogaster.
(c) GST-MED14 SPR and the point mutants indicated were captured on glutathione-agarose beads and subjected to in vitro ERK kinase assays
with 32P-g-ATP. Reactions were separated by SDS-PAGE and visualized by phosphor-imaging (upper panels) and Coomassie blue staining (lower
panels). Values indicate phosphate incorporation relative to wild-type (WT) fusion protein. (d) Full-length HA-tagged MED14 and the point mutants
indicated were immunoprecipitated from HEK293T cell lysates and subjected to in vitro kinase assays with rERK2* and 32P-g-ATP. Reactions were
separated by SDS-PAGE and visualized by phosphor-imaging (upper panel, 80% of IP). Relative recoveries were assessed by immunoblotting for
HA (lower panel, 20% of IP). (e) Phosphate incorporation into MED14 point mutants assayed as in (d) relative to wild-type (WT) protein (n=3,
error bars±SD).
10244 Nucleic Acids Research, 2013, Vol. 41, No. 22







not shown). Taken together, the data with the recombin-
ant SPR domain and the entire protein indicate that S986
is the primary, but not the sole, ERK phosphorylation site
in MED14.
The identiﬁcation of additional MED14 SPR domain
phospho-peptides besides those encompassing S986
suggests that the domain is a substrate for multiple
kinases. As such motifs are often CDK targets and
Mediator reversibly associates with the CDK8 complex,
we considered that CDK8 might also phosphorylate the
MED14 SPR domain. Co-immunoprecipitations with en-
dogenous and ectopically expressed proteins conﬁrmed that
CDK8 and MED14 interact (Supplementary Figure S2c
and d). We also detected MED12 (Supplementary
Figure S1b) and MED23 (Supplementary Figure S2c) in
CDK8 co-immunoprecipitates, which could conceivably
inﬂuence kinase activity. However, CDK8 immunopre-
cipitated either directly or indirectly with overexpressed
MED12 or MED14, failed to phosphorylate the recombin-
ant SPR domain of MED14, with or without parallel phos-
phorylation by rERK2* (Supplementary Figure S2e). We
therefore concluded that the SPR domain of MED14 is
unlikely to be a substrate for CDK8.
Phosphorylation of MED14 by ERK in vivo
To determine if S986 in MED14 is phosphorylated by
ERK in vivo, a phospho-speciﬁc antibody was developed.
In MED14, immunoprecipitates from HeLa cells, the anti-
pS986 antibody detected increased phosphorylation of
MED14 in response to serum stimulation that was abol-
ished by prior treatment of cells with the MAPK/ERK
Kinase (MEK) inhibitor U0126 (Figure 3a). To conﬁrm
that ERK was responsible for MED14 phosphorylation,
we used mutants of the Ras/ERK cascade. Activated
versions of Ras, Raf and MEK all stimulated phosphor-
ylation of MED14 and ERK, which could be substantially
blocked by U0126 but not by the p38 inhibitor SB290190
(Figure 3b). In contrast, active versions of
Phosphotidylinositol-3OH-kinase (PI3K), Akt/PKB, the
small G proteins RhoA, Rac1 and cdc42 and their down-
stream kinases SEK and PAK activated ERK weakly at
best and did not stimulate MED14 phosphorylation
(Supplementary Figure S3). Expression of a truncated
active version of MEKK1 (27) efﬁciently induced MEK-
dependent phosphorylation of S986 and also ERK
(Supplementary Figure S3, lane 3). Given the correlation
between ERK activation and MED14 phosphorylation in
these experiments, we conclude that S986 in MED14 is a
bona ﬁde target for ERK and mitogen signaling.
Importantly, the experiments do not rule out other sites
in the SPR domain as targets for alternative proline-
directed kinases activated by these pathways.
MED14 is required for efﬁcient IEG transcription
As phosphorylation of S986 in MED14 occurs in response
to mitogen or oncogene stimulation of ERK, we next
determined the contribution of MED14 to the regulation
of mitogen-responsive genes. First we tested the effect of
siRNA-mediated knockdown of MED14 in HeLa cells on
serum induction of several IEGs. Endogenous MED14
knockdown was achieved with a combination of two
MED14 siRNAs (Figure 4a, upper panel), with concomi-
tant loss of signal detected by the pS986 antibody (second
panel), which followed the activation of ERK induced by
serum (third panel). Parallel analysis of gene expression
by quantitative reverse transcriptase PCR revealed
that MED14 knockdown reduced the induction of c-fos
RNA by 50% at 15min (Figure 4b) and had a similar
effect on Egr1 induction (Figure 4c). MED14 knockdown
did not affect the expression of Mcl1, which in these cells
was relatively high and unresponsive to serum stimulation
(Supplementary Figure S4), indicating that MED14 deple-
tion does not inactivate Mediator per se.
If Elk-1 is required to recruit ERK for mitogen-induced
pS986 phosphorylation, loss of Elk-1 might abrogate this
modiﬁcation to MED14. We therefore examined the effect
of siRNA-mediated Elk-1 knockdown on the phosphoryl-
ation of pS986 in Mediator complexes isolated from HeLa
cells by immunoprecipitation with a CDK8 antibody.
Phosphorylation of MED14 in CDK8-Mediator complexes
was apparent in unstimulated cells (upper panel, Figure 4d,
lane 5) and increased upon mitogen stimulation (lane 6 and
Figure 3. ERK phosphorylates MED14 S986 in response to mitogenic
signals. (a) HeLa cells transfected with HA-MED14 were serum starved
for 16 h, treated with the MEK inhibitor U0126 (+) or a DMSO
control () for 2 h and harvested before () or after stimulation (+)
with 10% FCS for 15min. MED14 was recovered by immunopre-
cipitation from lysates (90% anti-HA, upper panel) and analyzed for
S986 phosphorylation with a phospho-speciﬁc antibody. MED14 ex-
pression levels and ERK activation levels were conﬁrmed by immuno-
blotting cell lysates (10%, lower panel). (b) HEK293 cells transfected
with HA-MED14 alone (1–3) or with active alleles of Ras (4–6), Raf-1
(7–9) or MEK (10–12) were serum starved for 16 h and treated with the
MEK inhibitor U0126, the p38 inhibitor SB290190 or DMSO control
for 2 h. MED14 expression, S986 phosphorylation and ERK activation
were monitored by immunoblotting cell lysates.
Nucleic Acids Research, 2013, Vol. 41, No. 22 10245







Figure 4e). Elk-1 knockdown (70%) reduced basal phos-
phorylation only slightly, but prevented mitogen-induced
phosphorylation of MED14 (compare lanes 7 and 8).
Thus, Elk-1 participates in ERK phosphorylation of
MED14 in CDK8-Mediator complexes.
To assess the contribution of MED14 phosphorylation
by ERK towards IEG induction, we attempted to rescue
the effect of MED14 knockdown with native and mutant
versions of siRNA-resistant MED14 expressed transiently
in HeLa cells from plasmids or in HCT116 cells from
lentiviral vectors (15). However, responses of HeLa cells
transfected with both siRNA and MED14 expression
vectors to mitogens were erratic and rescue attempts in
cells transduced with lentivirus were unsuccessful.
Nonetheless, the knockdown experiments conﬁrm a role
for MED14 in mitogen induction of IEGs, albeit with the
caveat that MED14 depletion may have pleiotropic effects
on Mediator structure and composition.
Figure 4. MED14 knockdown impairs IEG induction. Hela cells were mock transfected () or transfected twice with two MED14-targetting siRNAs
(+). After recovery for 24 h, serum was withdrawn for 16 h, cells were then stimulated for 0, 5, 15 or 30min with FCS and harvested for protein and
RNA extraction. (a) Analysis of MED14 knockdown, S986 phosphorylation and ERK activation by immunoblotting with the antibodies indicated.
(b and c) Analysis of MED14 knockdown on c-fos and egr1 RNA expression following serum stimulation by quantitative reverse transcriptase PCR.
Data represent mean values from three experiments each performed in triplicate. Multiple two-tailed t-tests (assuming equal SDs, with Holm-Sidak
correction using GraphPad Prism 6) were carried out to compare means (control versus MED14 KD) at each time point (n=3, P< 0.001 at 15min
and 30min for both c-fos and Egr1). (d) HeLa cells were mock transfected or transfected with Elk-1 siRNA, then serum-starved () or starved and
stimulated with TPA for 15min (+). CDK8 immunoprecipitates were collected from whole-cell lysates and the presence and phosphorylation of
MED14 was determined by SDS-PAGE and immunoblotting with the antibodies indicated (upper three panels). Lower panels of lysates indicate
extent of Elk-1 knockdown (70%) and of ERK activation (pERK). (e) Quantiﬁcation of pMED14/MED14 ratios in the experiment shown in (d).
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Mutation of S986 impairs oncogene and mitogen-induced
transcription
Given the inconclusive outcome from RNAi knockdown
and rescue experiments in assessing the contribution of
MED14 phosphorylation to IEG activation we turned to
gene reporter assays. First we transfected a Ras-responsive
reporter gene carrying multimerized ETS binding sites, to
which Elk-1 and other ETS factors bind (28), into
HEK293 cells. Expression of MED14 doubled the tran-
scriptional response to active Ras and this effect was sig-
niﬁcantly impaired by the S986A substitution (Figure 5a).
To focus speciﬁcally on Elk-1-dependent gene expres-
sion in response to mitogens we turned to a Gal4 reporter
and the well-documented Elk-1 fusion protein consisting
of the Gal4 DNA binding domain in place of the ETS
domain (Gal-Elk) (18,29). Initial experiments were incon-
clusive because MED14 expression inﬂuenced both re-
porter and control genes. However, in NIH3T3 cells we
were able to achieve comparatively stable control gene
expression by switching promoters (see Supplementary
Figure S5a), whereupon MED14-S986A signiﬁcantly
reduced mitogen-induced reporter expression when
compared with native MED14 (Figure 5b). This effect is
apparent even though endogenous MED14 is present in
the cells. Western blots conﬁrmed that expression levels
of MED14 and MED14-S986A were indistinguishable
in both HEK293 and NIH3T3 cells (Supplementary
Figure S5b).
The observation that ectopic expression of a core com-
ponent of Mediator was able to inﬂuence a control gene
led us to explore whether MED14 expression and its phos-
phorylation on S986 had a generic inﬂuence on multiple
transcriptional activators. Elk-1 is one of three TCFs, the
others being Net (Elk-3) and Sap1 (Elk-4) (3,4). Like
Elk-1, when Sap1 is fused to Gal4 (Gal-Sap) it also
mediates induction of Gal4 reporter expression in
response to mitogens. In this case, however, expression
of MED14-S986A did not impair reporter expression
(Figure 5c).
At some promoters, Elk-1 forms ternary complexes with
SRF in competition with Myocardin-like factors. A Gal4
fusion containing the activation domain of MKL1 (507–
931) (30) was also active, but only weakly responsive to
12-O-tetradecanoylphorbol-13-Acetate (TPA), and
although MED14 expression reduced basal expression,
there was no difference between native MED14 and
MED14-S986A (Figure 5d). Other studies describe cross-
talk between ERK and transforming growth factor beta
(TGFb) signaling (31,32). We therefore also tested
SMAD2-dependent gene expression using a Gal4 fusion
with the CTD of XfoxH1b, which carries Fast/FoxH1 and
SMAD interacting motifs (33). Again, ectopic expression
of either MED14 or the S986A mutant had no signiﬁcant
effect on TGFb-induced reporter expression (Figure 5e).
Taken together, these data indicate that ERK phosphor-
ylation of MED14 contributes positively to mitogen-
Figure 5. S986 mutation impairs Ras- and mitogen-induced reporter expression. (a) HEK293 cells were transfected with an E74-Luc reporter and
TK-Renilla control, expression vectors for MED14, MED14-S986A or corresponding vector (pRK5) and V12-Ras or corresponding vector (pCMV5).
After 36 h cell gene expression was analyzed by ﬂuorescence assay. Data represent mean values from three independent experiments each performed
in triplicate (P< 0.001). (b–d) NIH3T3 cells were transfected with a Gal4-Luc reporter and UbC-Renilla control, expression vectors for MED14,
MED14-S986A or corresponding vector (pRK5) and Gal4(1–143) or Gal4-protein fusions with activation domains of Elk-1, Sap1a or MKL1,
respectively. After serum-starvation for 24 h, cells were left untreated () or stimulated with TPA for 6 h (+). Data in (b) represent mean values from
four experiments, in (c) and (d) from three experiments, all performed in triplicate. (e) NIH3T3 cells were transfected with a Gal4-Luc reporter and
UbC-Renilla control, expression vectors for MED14, MED14-S986A or corresponding vector (pRK5) and Gal4(1–95) or a Gal4 protein fusion with
FM/SIM SMAD recruitment motifs. After serum-starvation for 24 h, cells were left untreated () or stimulated with TGFb for 6 h (+). Data
represent mean values from three experiments each performed in triplicate.
Nucleic Acids Research, 2013, Vol. 41, No. 22 10247







induced gene expression mediated by Elk-1 and possibly by
other ETS factors. Moreover, this effect is selective, as the
activity of several other transcriptional activators is
unimpaired by the S986A substitution in MED14.
MED14 phosphorylation induced at IEG promoters
The recruitment of active ERK by Elk-1 to mitogen-
responsive gene promoters implicates them as locations
at which phosphorylation of MED14 may occur. In chro-
matin immunoprecipitation (ChIP) experiments with
HCT116 cells, mitogens stimulated the recruitment of
MED14 to the c-fos promoter region (Figure 6a), in line
with observations for other Mediator components (19,34).
Mediator recruitment was accompanied by a substantial
increase in MED14 phosphorylation on S986. Little
change in promoter occupancy by RNAPII was
observed, in agreement with previous reports (15), but
whereas RNAPII was restricted to the TATA box region
in unstimulated cells, its presence on the gene was apparent
after stimulation. As anticipated, similar patterns of
occupation and phosphorylation were observed at the
Egr1 promoter (Figure 6b). Thus, phosphorylation of
MED14 on S986 at the promoters of these two IEGs
accompanies their transcriptional activation by mitogens.
Using lentiviral-mediated knockdown we were able to
reduce MED14 levels at the Egr1 and c-fos promoters by
50% in serum-stimulated cells (Figure 6c and
Supplementary Figure S6) with concomitant decreases in
S986 phosphorylation. MED14 knockdown was
associated with reductions in RNAPII occupation and
CDK8 recruitment within the timeframe of mitogen
stimulation. In addition, we observed decreased phos-
phorylation of the CTD, in the case of phospho-serine 5
at the promoter and for phospho-serine 2 also along the
genes (Figure 6c and Supplementary Figure S6). These
reductions are consistent with the impairment of c-fos
and Egr1 transcription seen with MED14 siRNA
(Figure 4b and c). Taken together, these data conﬁrm
the participation of MED14 and its phosphorylation on
S986 in the transcriptional activation of the c-fos and Egr1
genes in response to mitogens.
Figure 6. MED14 phosphorylation at IEG promoters. (a) ChIP analysis of MED14 recruitment (upper graph), S986 phosphorylation (middle) and
RNAPII occupation (bottom) at the c-fos gene in starved (light blue) or serum stimulated (dark blue) HCT116 cells. Data represent mean values
from three experiments as mean percentage of maximal signal at each locus (in ng of input DNA). (b) ChIP analysis as in (a) of MED14 recruitment
(upper graph) S986 phosphorylation (middle) and RNAPII occupation (bottom) at the Egr1 gene. Data represent mean values from four experiments
as mean percentage of maximal signal at each locus (in ng of input DNA). (c) HCT116 cells expressing MED14 shRNA or control cells were serum
starved or starved and treated with serum for 30min. RNAPII occupation and CDK8 recruitment (upper graphs), MED14 recruitment and S986
phosphorylation (middle), pS5-CTD and pS2-CTD modiﬁcations (bottom) at the Egr1 gene were determined by ChIP assay. Data represent mean
values from three experiments as mean percentage of maximal signal at each locus (in ng of input DNA).
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Elk-1 interactions with MED14
Elk-1 is thought to contact Mediator through phosphor-
ylation-dependent interactions with MED23 (17). As
MED23 co-immunoprecipitates efﬁciently with MED14
and CDK8 (see e.g. Supplementary Figure S2c), we
reasoned that an indirect interaction between Elk-1 and
MED14 might also be detectable. Indeed, in MED14
co-immunoprecipitates from HeLa cells, we observed
MED23 and also Elk-1 (Figure 7a, lane 5). In co-
immunoprecipitates from mitogen-stimulated cells, we
also detected phospho-Elk-1 (lane 6). These ﬁndings
could be recapitulated in HEK293T cells expressing
tagged versions of MED14 and Elk-1 (Figure 7b and
Supplementary Figure S7a), phosphorylated Elk-1 only
Figure 7. Elk-1 interacts with MED14 independently of MED23. (a) Lysates were prepared from serum-starved () or TPA-stimulated (+) HeLa
cells (lanes 1 and 2). Control (lanes 3 and 4) or MED14 (lanes 5 and 6) co-immunoprecipitates were collected and analyzed in parallel by SDS-PAGE
and immunoblotting for the presence of phospho-Elk (upper), Elk-1, MED23 and MED14 (lower panel) with the antibodies indicated. (b) HEK293
cells were transfected with vectors for tagged versions of MED14 and Elk-1 as indicated. Cells were serum-starved (lanes 1–3), treated with EGF
alone (lane 4) or with EGF after prior addition of the p38mapk inhibitor SB290190 (lane 5). Lysates were prepared, MED14 co-immunoprecipitates
were collected with an anti-HA antibody and analyzed by SDS-PAGE and immunoblotting for the presence of phospho-Elk (upper), Elk-1, MED23
and MED14 (lower panel) with the antibodies indicated left. Immunoblots of corresponding lysates are shown in the panels below. (c) HEK293 cells
were transfected with vectors for tagged versions of MED14 and Elk-1 as indicated. Lysates were prepared from serum-starved cells (lanes 1, 3, 5 and
7) or cells treated with EGF (lanes 2, 4, 6 and 8). Co-immunoprecipitates were collected from the lysates with an anti-HA antibody (lanes 1–4), an
anti-MED23 antibody (lanes 5 and 6) or with an anti-HA antibody from the post MED23 IP lysates (lanes 7 and 8). Samples were analyzed by SDS-
PAGE and immunoblotting for the presence of phospho-Elk (upper), Elk-1, MED23 and MED14 (lower panel) with the antibodies indicated left.
Upper bands in lanes 3, 4, 7 and 8 of MED23 panel are from previous exposure to MED14 antibody. Immunoblots of corresponding lysates are
shown in the panels below. (d) MED23 wt (lanes 1–4) and MED23/ MEFs (lanes 5 and 6) were transfected with a vector for Elk-1, and lysates
were prepared from serum-starved cells (lanes 1, 3 and 5) or cells treated with TPA (lanes 2, 4 and 6). Mock (lanes 1 and 2) or MED14
co-immunoprecipitates (lanes 3–6) were collected from the lysates and samples were analyzed by SDS-PAGE and immunoblotting for the
presence of Elk-1 (upper), MED23 (middle) and MED14 (lower panel). Immunoblots of corresponding lysates are shown in the panels below.
(e) Lysates were prepared from MED23 wt (lanes 1, 3 and 5) and MED23/ MEFs (lanes 2, 4 and 6) transfected with a vector for Elk-GFP. Mock
(lanes 1 and 2), MED14 (lanes 3 and 4) or control IgG co-immunoprecipitates (lanes 5 and 6) were collected from the lysates, and samples were
analyzed by SDS-PAGE and immunoblotting for the presence of Elk-GFP (upper), MED23 (middle) and MED14 (lower panel). Immunoblots of
corresponding lysates are shown in the panels below. (f) MED23/ and MED23 wt MEFs were transfected with Gal4-Luc reporter, Gal-Elk
expression vector and UbC-Renilla control. After serum-starvation for 24 h, cells were left untreated () or stimulated with TPA for 6 h (+). Data
represent mean values from three experiments each performed in triplicate.
Nucleic Acids Research, 2013, Vol. 41, No. 22 10249







being present after mitogen stimulation and more
apparent when ERK signaling was enhanced with the
p38 inhibitor SB290190 (Figure 7b, lane 5). Nonetheless,
the amount of Elk-1 was similar under all conditions.
These results indicate that a fraction of Elk-1 contacts
Mediator regardless of gene activation state, which is con-
sistent with the detection of Elk-1 and several Mediator
subunits at IEG promoters in unstimulated cells (19).
The data above suggest that Elk-1-Mediator interactions
involving MED23 may not be contingent on Elk-1 phos-
phorylation. To assess this we performed MED14 and
MED23 co-immunoprecipitations in parallel. Elk-1 was
present in both MED14 and MED23 co-immunopre-
cipitates (Figure 7c, lanes 3–6). However, phospho-Elk-1
was present in MED14 but not in MED23 co-immunopre-
cipitates collected from mitogen-stimulated cells (compare
lanes 4 and 6). To explain this result, we surmised that the
MED23 antibody preferentially recognizes a Mediator-
independent population of MED23. Indeed, when
MED14 was immunoprecipitated from cell lysates after
immunoprecipitation of MED23, Elk-1, phospho-Elk-1
and MED23 were all detected (lanes 7 and 8). This result
indicates that phospho-Elk-1 only interacts with MED23 in
a complex with MED14.
If the observed association between MED14 and Elk-1
were dependent on MED23, Elk-1 would unlikely be
present in MED14 co-immunoprecipitates from cells
lacking MED23. To test this we performed experiments
with MED23wt and MED23/ MEFs. In fact the asso-
ciation of MED14 and Elk-1 was equally apparent in
MED23wt and MED23/ MEFs, even though expres-
sion of Elk-1 was somewhat lower in MED23/ MEFs
(Figure 7d, compare lanes 3 and 5). This result was con-
ﬁrmed with an Elk-GFP fusion protein (Figure 7e). Thus
without MED14, MED23 does not contact phospho-Elk,
whereas Elk-1 is able to contact Mediator independently
of MED23. Moreover, MED14 phosphorylation increases
following mitogen stimulation in both MED23wt and
MED23/ MEFs (Supplementary Figure S7b).
Nonetheless, Gal-Elk fails to activate reporter expression
in response to mitogens in MED23/ cells (Figure 7f),
consistent with MED23 acting in a post-recruitment
step (34).
DISCUSSION
Our studies have revealed that active ERK is recruited by
Elk-1 into PICs at mitogen-responsive promoters and
phosphorylates MED14 on S986. This phosphorylation
event at IEG promoters contributes to transcriptional ac-
tivation, as an alanine substitution at S986 causes signiﬁ-
cant reductions in Ras-induced and mitogen-stimulated
gene expression. Phosphorylation of S986 by ERK may
be facilitated by Elk-1 interactions with MED14, which
are detected before mitogen stimulation and in cells
lacking MED23. Our data are consistent with a role for
MED23 in post-recruitment events that may include con-
formational changes to Mediator induced by phosphoryl-
ation of MED14.
MED14 phosphorylation and structure
Serine 986 is one of 14 S/TP motifs deﬁning a SP-rich
(SPR) domain in MED14 that appears to undergo
multiple phosphorylations by hitherto unidentiﬁed
kinases. All bar one MED14 phospho-peptides identiﬁed
to date in proteomic screens map to this region. Only 5 S/
TP motifs (including S986) conform to the ERK consen-
sus, of the others, three (S1119, S1136 and S1146) are
phosphorylated in MV4-11, HCT116 and/or HEK293
cells, as are two adjacent serines (S1133 and S1144)
(24–26). Our data establish ERK as the S986 kinase; they
also rule out phosphorylation of the SPR domain by
CDK8. Importantly, they do not exclude phosphorylation
of sites other than S986 by alternative proline-directed
kinases. Phosphorylation site prediction algorithms
identify 21 high conﬁdence sites, of which 12 are SP
motifs. Other kinases predicted to phosphorylate the
SPR domain include ATM and IKK (35,36). Thus the
SPR domain in MED14 may serve as an integration
point for multiple pathways that inﬂuence Mediator
function.
Early genetic experiments in yeast complemented by
fractionation and reconstitution studies predicted the
modular nature of Mediator. EM studies later revealed a
three-lobed structure with head, body and tail domains
(12). MED14, the product of an essential gene in yeast
(Rgr1), is a core structural component of the tail
domain, acting as a scaffold for several submodules
deﬁned by MED9, MED10 and MED15 (Gal11).
Genetic deletion of Gal11 in yeast yielded a Mediator
complex lacking the entire Gal11 module and rendered
RNAPII defective for activated but not basal transcrip-
tion (37). Subsequent identiﬁcation of Gal11 subunits
(MED2, 3, 15 and 16) as co-activators for numerous mam-
malian transcription factors has reinforced the notion of
the tail domain as the entry point for regulatory input to
the RNAPII holoenzyme. In line with this model, loss of
MED24 impairs the incorporation of MED23 into
Mediator and vice versa (17,38).
Interpretations of interaction studies in yeast inferred
that tail domain subunits of the Gal11 submodule (e.g.
MED16) contact the C-terminal part of MED14, while
regions of MED14 further N-terminal interact with
MED9 and MED10 submodules, which form part of the
body domain (39,40). Extrapolating from this
organization to the metazoan counterpart, the SPR
domain of MED14 could provide an articulation point
between body and tail of Mediator. Although sequence
comparisons provide no clues to domain structures in
MED14 and structural data are presently unavailable,
the regular distribution of S/TP motifs with a mean
spacing of 8.5 and protein structure predictions suggest
a domain with conformational ﬂexibility. Nonetheless,
recombinant versions of the MED14 SPR domain are
soluble and structural studies may be informative.
MED14 phosphorylation and IEG
transcriptional activation
MED14 participates in hormone-responsive gene expres-
sion (41). Using RNAi we extended its role to include
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mitogen-responsive gene expression, with induced levels of
c-fos and Egr1 RNA being decreased 50% by a similar
degree of MED14 knockdown. In contrast, Mcl1 expres-
sion was unaltered, suggesting that this reduction was
unlikely to result from a pleiotropic defect to Mediator.
ChIP analyses further indicated that the lower levels of c-
fos and Egr1 RNA correlated with reductions in both
CDK8 and RNAPII occupation at the two promoters
and a decrease in pS2-CTD density along the genes.
Reporter gene assays provided evidence for a role of
MED14 phosphorylation on S986 in IEG induction.
Ras-dependent activation of an ETS-responsive reporter
in HEK293 cells increased substantially on co-expression
of MED14 but signiﬁcantly less with the S986A mutant,
implicating ERK phosphorylation of MED14 in prolifera-
tive gene expression. In addition, we were able to demon-
strate a signiﬁcant dominant-negative impact of the
S986A point mutation on Elk-1 transactivation. Again
this effect was speciﬁc, as no signiﬁcant difference was
observed with analogous reporters for Sap1a, MKL1 or
SMAD2/3.
Phosphorylation of MED14 increased rapidly and sub-
stantially at the c-fos and Egr1 promoters after mitogen
stimulation (20 - and 4-fold after 30min respectively),
promoters to which Elk-1 recruits ERK (19). These
earlier knockdown experiments have now been extended
to highlight the role of Elk-1 in MED14 phosphorylation
by ERK (Figure 4d). On the c-fos promoter
phosphorylated MED14 was restricted to a peak at the
region around 30 (Figure 6a), consistent with phosphor-
ylation of MED14 within the recruited RNAPII holoen-
zyme. Phosphorylated MED14 also accumulated and
co-localized with increases in CDK8 recruitment and S5-
CTD phosphorylation (Figure 6c). These data are consist-
ent with a model in which ERK phosphorylates MED14
within PICs as a positive post-recruitment step during
IEG induction.
Elk-1 interactions with MED14 and Mediator
MED23 co-immunoprecipitates efﬁciently with MED14,
so the presence of Elk-1 in MED14 co-immunopre-
cipitates was anticipated, given the essential contribution
of MED23 to the Elk-1-dependent activation of IEGs
and the induction of adipogenesis (17,18). However, in
contrast to published data, our ﬁndings with endogenous
proteins in HeLa cells and tagged versions of MED14 and
Elk-1 in HEK293T cells indicated that unphosphorylated
and phosphorylated Elk-1 interact similarly with
Mediator. Moreover, phospho-Elk-1 was co-immunopre-
cipitated with MED14, but not with MED23, while inter-
actions between MED14 and Elk-1 could be detected
equally well in MED23/ and MED23 wt MEFs. To
explain the ﬁrst point we infer that the MED23 antibody
immunoprecipitates a pool of free MED23 but is unable to
recognize MED23 associated with Mediator. This may
have a bearing on the interpretation of earlier work,
although the implications of a free pool of MED23 are
presently unclear. From the second, we conclude that
MED23 is not essential for the interaction between Elk-
1 and MED14, nor, apparently, for MED14
phosphorylation (Supplementary Figure S7b), and infer
that the crucial role of MED23 is not as intermediary in
the recruitment of Mediator by Elk-1.
Recently, Yin et al. showed that MED23/ MEFs
were predestined to a smooth muscle cell phenotype,
concluding that the absence of MED23 allowed
Myocardin-like factors to predominate over TCFs at
common target gene promoters (42). Our data imply
that in MED23/ MEFs Elk-1 would not be precluded
from PIC formation at such promoters but would be
unable to stimulate post-recruitment events. This
scenario is fully consistent with an earlier conclusion
that MED23 serves its co-activator function during the
post-recruitment phase of transcription (34).
MED14 has been linked to transcriptional regulation
of hormone-responsive genes in conjunction with
MED1. Two transactivation domains of the glucocortic-
oid receptor cooperate independently with MED1 and
MED14 (23). Similarly, PPARg, which was initially
shown to require MED1, also interacts with MED14 via
its N-terminal domain (43). At present we have no
evidence to indicate that Elk-1 interacts directly with
MED14. Submodules containing MED9, MED10 and
MED16 all contact Mediator via MED14, providing
several alternatives, although the absence of MED16
and MED24 from Mediator complexes in MED23/
cells appears to exclude them as targets. However, the
link between Elk-1 and MED23 is no less enigmatic.
The Elk-1 activation domain was shown to bind HeLa
Mediator in a phosphorylation-dependent manner, but
the interaction was not clearly dependent on MED23
(17). Furthermore, no biochemical dissection of the
MED23 interaction with Elk-1 has been forthcoming,
whereas two Drosophila transcriptional activators could
be shown to interact directly with a 270aa fragment of
dMED23 (48% identical to hMED23) (44). In summary,
by whatever means, Elk-1 communicates with Mediator,
our ﬁnding that an interaction can be established inde-
pendently of MED23 suggests that the documented asso-
ciation between Elk-1 and MED23 may ultimately prove
to be crucial for post-recruitment operations involving
Mediator.
MED14 phosphorylation and Mediator function
How might MED14 phosphorylation promote IEG tran-
scription? Mediator acts as a central scaffold for PIC
assembly, interacting with its dedicated kinase module,
the basal transcription machinery and RNAPII (12).
Thus, modiﬁcation of S986 may control accessibility to
Mediator, by the creation or disruption of a critical
docking site. For example, 14-3-3 proteins recognize a
range of phospho-serine containing partners; conversely,
phosphorylation of the GS- region of TGFbRI blocks
binding by FKBP12 (45,46). We did not detect a change
in the global association of CDK8 and MED14 upon
mitogen stimulation of HeLa cells (accompanied by
MED14 phosphorylation), possibly because such
changes are likely to be dynamic and restricted to a
small fraction of Mediator. Additionally, phosphorylation
site mutations in MED14 had no impact on its association
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with CDK8 (LL and PES, unpublished). However, these
experiments did not rule out other changes to CDK8-
associated Mediator complexes.
The conformation of Mediator differs between forms
bound to CDK8 and RNAPII (41) and it has been
shown to undergo structural shifts triggered by inter-
actions with the transactivation domain of p53 that
correlated with RNAPII activation (47). Conceivably,
phosphorylation offers a potent mechanism to inﬂuence
Mediator conformation. Interestingly, the WW domain-
containing protein Pin1 is an isomerase implicated in IEG
induction that recognizes phospho-serine/threonines,
allowing kinases and phosphatases to exploit conform-
ational change around peptidyl-prolyl bonds (48).
Indirect evidence attests to a key role for the
SPR domain in MED14 function. Deletion of the SPR
domain from MED14 (MED14) generated a mutant
that no longer accumulated in the nucleus (unpublished),
hence its exclusion from functional assays, suggesting that
the SPR domain might be required for MED14 incorpor-
ation into Mediator. However, interaction studies in yeast
suggest that the SPR domain nestles between regions of
MED14 with which diverse submodules interact. It would
thus be ideally positioned to engage in post-recruitment
conformational changes to Mediator that could result
from its phosphorylation by ERK and, potentially,
several other kinases. Furthermore, MED14 is just one
of multiple ERK targets within Mediator, as MED1 and
at least one other Mediator subunit are phosphorylated by
ERK (22) (and our unpublished data). ERK recruitment
by different transcriptional activators or mechanisms (49)
may dictate its target selection within Mediator.
Alternatively, multiple contemporaneous phosphorylation
events could have a synergistic effect on Mediator con-
formation unlikely to be abrogated by individual point
mutations in a single Mediator subunit. Either way, our
demonstration that ERK is recruited into PICs by the
activation domain of Elk-1 to phosphorylate the core
Mediator component MED14 and promote transcription
highlights a new aspect to post-recruitment regulation of
IEG expression.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online,
including [50–52].
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